Education
About Us
Working with TipRanks
Follow Us
INNOVATE Corp (VATE)
NYSE:VATE
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
0.98Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: -1.44%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with strong performance and strategic achievements in the Life Sciences and Broadcasting segments, but was offset by significant revenue declines and increased debt levels affecting the overall financial health.Company Guidance
During INNOVATE's Q1 2025 earnings call, the company reported consolidated revenues of $274.2 million and an adjusted EBITDA of $7.2 million. The Infrastructure segment, led by DBM Global, achieved revenues of $264.9 million and an adjusted EBITDA of $16.7 million, with a notable gross margin improvement of 110 basis points year-over-year to 15.6%. The Life Sciences segment saw revenues increase by 210% to $3.1 million, driven by R2's performance, which also showed a significant gross worldwide system unit sales surge of 163% over the previous year. Spectrum's revenues were $6.2 million with an adjusted EBITDA of $1.4 million, reflecting stable results year-over-year. The company also noted a reported backlog of $1.4 billion for DBM Global, with ongoing efforts to mitigate potential impacts from tariffs. INNOVATE ended the quarter with $33.3 million in cash and cash equivalents and a total outstanding indebtedness of $672 million.Strong Segment Performance in Infrastructure and Life Sciences
DBM Global's revenues reached $264.9 million with adjusted EBITDA of $16.7 million, showing gross margin improvement by 110 basis points to 15.6%. Life Sciences revenue increased 210% to $3.1 million, driven by R2's performance with unit sales surging 163% year-over-year.
Significant Achievements in Life Sciences
MediBeacon received FDA approval for its transdermal GFR system and the National Medical Products Administration in China also approved it. The TGFR system is set for commercial sale in Q4 2025.
R2's Impressive Growth
R2 tripled its year-over-year revenue to $3.1 million in Q1 2025 with a 109% increase in North America and global unit sales up 163%. Social media engagement and website users also saw tremendous growth.
Strategic Developments in Broadcasting
Spectrum signed a contract with Marathon Ventures for new networks and filed a petition with the FCC for 5G broadcast technology, indicating forward-thinking strategies in the broadcasting segment.
---
VATE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VATE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 06, 2025 | $6.24 | $6.15 | -1.44% |
| Mar 31, 2025 | $7.83 | $7.31 | -6.64% |
| Nov 06, 2024 | $5.14 | $5.16 | +0.39% |
| Aug 07, 2024 | $5.65 | $5.25 | -7.08% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does INNOVATE Corp (VATE) report earnings?
INNOVATE Corp (VATE) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is INNOVATE Corp (VATE) earnings time?
INNOVATE Corp (VATE) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VATE EPS forecast?
Currently, no data Available
---